The Australian Competition and Consumer Commission today released a Statement of Issues on Nestlé’s proposed acquisition of Pfizer Nutrition.
The Statement of Issues seeks further information on certain competition issues which have arisen from the ACCC's review to date as well as the broad principles of a proposed remedy offered by Nestlé to address potential competition concerns which may arise as a result of the proposed acquisition.
While the ACCC has agreed to consult on the broad principles of the proposed remedy put forward by Nestlé, the ACCC is not currently in a position to form a concluded view as to the necessity, efficacy or acceptability of the proposed remedy offered.
The ACCC invites further submissions from the market in response to the Statement of Issues by 14 September 2012. As a result, the ACCC's final decision will be deferred until 11 October 2012.